miR-16在T淋巴母细胞淋巴瘤/急性淋巴母细胞白血病中表达  

Expression of miR-16 in Patients with T Lymphoblastic lymphoma/Acute Lymphoblastic Leukemia

作　　者：童来根[1] 吴文忠[1] 张云平[1] 周志刚[1] 陈亚峰[1] 黄文娟[1] 许欢[1] 苏倩倩[1] 

机构地区：[1]宜兴市人民医院血液内科,江苏宜兴214200

出　　处：《中国实验血液学杂志》2014年第1期99-103,共5页Journal of Experimental Hematology

摘　　要：本研究探讨miR-16在T淋巴母细胞淋巴瘤/急性淋巴母细胞白血病(T-LBL/ALL)中的表达及其与预后的关系。应用免疫组织化学法对宜兴市人民医院血液科有详细随访资料的38例T-LBL/ALL石蜡标本进行CD3、cCD3、CD10、CD20、CD34、CD43、CD99、TdT、PAX-5、BCL-2和Ki67免疫组织化学标记检测,采用real-time RT-PCR方法检测miR-16的表达水平,以15例淋巴结反应性增生作为对照。结果表明:38例T-LBL/ALL中TdT阳性率最高(94.7%),CD34阳性最低(22.1%),PAX-5及CD20为阴性。在39.5%病例中Ki67大于80%。与淋巴结反应性增生相比较,miR-16在T-LBL/ALL中表达上调,其表达量是淋巴结反性增生的4.87倍(P<0.05)。T-LBL中miR-16高表达组总体生存率下降(P<0.05)。BCL-2蛋白表达阳性组预后优于阴性组预后(P<0.05)。miR-16表达与BCL-2蛋白存在相关性(r=0.51,P<0.05)。结论:在T-LBL/ALL中miR-16的高表达组总体生存率明显高于低表达组,提示miR-16可能与预后有相关性,而BCL-2蛋白表达阳性组预后好于阴性组,可能也是一种影响预后的因素。This study was purposed to investigate the expression of miR-16 in T lymphoblastic lymphoma/acute lymphoblastic leukemia （T-LBL/ALL） and its relation with target therapy and prognosis.The CD3、cCD3 、CD10、CD20 、CD34、CD43、CD99、TdT、PAX-5、BCL-2 and Ki67 in paraffin samplcs from 38 cases of T-LBL/ALL were detected by immunohistochemical labeling; the miR-16 expression level was detected by real-time RT-PCR.Fifteen cases of reactive hyperplasia of lymphonodes were selected as control.The results indicated that among 38 cases of T-LBL/ALL the positive rate of TdT was highest （94.7％）,the positive rate of CD34 was lowest （22.1％）,the PAX-5 and CD20 were found to be negative.The Ki67 expression level in 39.5％ cases exceeded 80％.As compared with reactive hyperplasia of lymphonode,the miR-16 expression in T-LBL/ALL was up-regulated,ant its expression level was 4.87-fold of reactive hyperplasia of lymphonode （P ＜ 0.05）.The overall survival rate in group of miR-16 high expression decreased （P ＜ 0.05）.The prognosis of T-LBL/ALL patients with BCL-2 positive expression was better than that of patients with BCL-2 negative expression （P ＜ 0.05）.The miR-1 6 expression correlated with BCL-2 protein （r =0.51,P ＜0.05）.It is concluded that the overall survival rate in miR-16 high expression group is higher than that in miR-16 low expression group,suggesting possible relation of miR-16 with prognosis.Moreover,the prognosis in BCL-2 positive expression group is better than that in negative expression group,which may be a factor influencing prognosis.

关 键 词：miR-16 淋巴瘤 T淋巴母细胞淋巴瘤 急性淋巴母细胞白血病 

分 类 号：R733.1[医药卫生—肿瘤] R733.7[医药卫生—临床医学]